AACR-NCI-EORTC International Conference: Charles Swanton Interview

Professor Charles Swanton, a medical oncologist at The Francis Crick Institute and UCL Cancer Institute, London, UK, discusses the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications which will be held from 26 to 31 October 2017 in Philadelphia, USA. As the EORTC scientific co-chair of the meeting, he explains the overarching themes of the conference and the topics that will be presented at the meeting.

Abstracts are now available, key studies that will be presented include:

• Characterization of antitumor activity of TAS6417, a novel EGFR-TKI targeting exon 20 insertions
  Shinichi Hasako, Taiho Pharmaceutical Co., Ltd., Tsukuba, Japan
• EGFR-CD3 bispecific Probody™ therapeutic induces tumor regressions and increases maximum tolerated dose >60-fold in preclinical studies
  Leila Boustany, CytomX Therapeutics, Redwood City, California
• Neratinib has clinical activity in HER2-amplified breast cancer patients with tumors that have acquired activating mutations in HER2
  Maurizio Scaltriti, Memorial Sloan Kettering Cancer Center, New York, New York
• Loss of the lysosomal transporter SLC46A3 is a mechanism for innate and acquired resistance to non-cleavable maytansine and pyrrolobenzodiazepine-based antibody- drug conjugates
  Krista Kinneer, Medimmune, Inc., Gaithersburg, Maryland
• AG-120 (ivosidenib), a first-in-class mutant IDH1 inhibitor, promotes morphologic changes and upregulates liver-specific genes in IDH1 mutant cholangiocarcinoma
  Vikram Deshpande, Massachusetts General Hospital, Boston, Massachusetts
• Phase 1 study of the EZH2 inhibitor, tazemetostat, in children with relapsed or refractory INI1-negative tumors including rhabdoid tumors, epithelioid sarcoma, chordoma, and synovial sarcoma 
  Susan N. Chi, Dana-Farber Cancer Institute, Boston, Massachusetts
• First in human, dose escalation trial of the combination of dabrafenib, trametinib, and navitoclax in patients with BRAF mutant solid tumors
  Ryan J. Sullivan, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts
• Preliminary results from a phase 2 proof of concept trial of tipifarnib in tumors with HRAS mutations
  Alan L. Ho, Memorial Sloan Kettering Cancer Center, New York, New York
• Durable responses observed in recurrent high-grade glioma (rHGG) with Toca 511 and Toca FC treatment
  Clark Chen, University of Minnesota, Minneapolis, Minnesota
• Allele specific HLA loss and immune escape in lung cancer evolution
  Rachel Rosenthal, University College London, London, England
• Immunoediting in untreated mismatch repair deficient colorectal cancer
  Danny Wells, Parker Institute for Cancer Immunotherapy, San Francisco, California
• Prediction of clinical outcomes of cancer patients treated with anti‑PD‑1/PD‑L1 using a radiomics-based imaging score of immune infiltrate
  Roger Sun, Institut Gustave Roussy, Villejuif, France

This highly anticipated annual conference, which alternates each year in USA and Europe, will again present cutting edge data. To view the programme and to find out how to register, please view here.